stocks logo

CHE Earnings

Chemed Corp
$
432.140
-3.19(-0.733%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

Earning Analysis

Welcome to our in-depth analysis of Chemed Corp(CHE) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Chemed Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.

Earnings Forecast

Revenue
EPS
Currency: USD
Actual
Estimate

Surprise Analysis

Name
EPS
Revenue
Price Reaction
Fiscal QuarterEarning DateTimeEstimateActualSurprise%EstimateActualSurprise%1D5D
FY2025Q22025-07-29After Hours4.914.27-13.03623.93M618.80M-0.82-10.36-8.90
FY2025Q12025-04-23After Hours5.555.63+1.44641.78M646.94M+0.80-6.61-1.79
FY2024Q42025-02-26After Hours6.786.83+0.74636.10M639.99M+0.61+7.39+9.05
FY2024Q32024-10-29After Hours5.765.64-2.08612.22M606.18M-0.99-12.14-12.57
FY2024Q22024-07-24-5.145.01-2.53599.20M595.88M-0.55+1.14+4.59
FY2024Q12024-04-24-5.094.68-8.06591.10M589.23M-0.32+0.23-7.87
FY2023Q42024-02-27-6.256.60+5.60586.64M585.91M-0.12-0.31+5.61
FY2023Q32023-10-25-4.925.32+8.13558.42M564.53M+1.10-0.02+10.95
FY2023Q22023-07-26-5.094.71-7.47562.54M553.82M-1.55+0.04-8.02
-2023-04-26-4.384.39+0.23----0.82-3.01

CHE Earnings Analysis

Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Chemed Corp reported performance for FY2025Q2, announced on 2025-07-29. The company achieved an EPS of 4.27, compared to analyst estimates of 4.91 by -13.03% . Revenue for the quarter reached 618.80M compared to expectations of 623.93M by -0.82% .
The stock price reacted with a -10.36% one-day change and a -8.90% five-day change following the earnings release. These movements reflect market reaction in Chemed Corp growth trajectory and strategic initiatives.

CHE Earnings Forecast

Looking ahead, Chemed Corp(CHE) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 629.36M and an EPS of 5.36.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -2.27%, while EPS estimates have been Revise Downward by -9.84%. For the upcoming Q3 2025, revenue estimates have been adjusted Revise Downward by -3.8% . These revisions correlate with a -24.07% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Chemed Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

Estimate Revision

The chart shows the correlation between CHE's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.27%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-9.84%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Downward
down Image
-3.8%
In Past 3 Month
Stock Price
Go Down
down Image
-24.07%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
--
Revenue Estimate-Annual FY 2025:2.55B
--
EPS Estimate-Annual FY 2025:22.11
Stock Price432.14

CHE Revenue and EPS Performance: A Historical Perspective

Chemed Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-07-29,After Hours):
EPS: 4.27 (Actual) vs.4.91 (Estimate) (-13.03%)
Revenue: 618.80M (Actual) vs. 623.93M (Estimate) (-0.82%)
Price Reaction: -10.36%(1-Day), -8.90%(5-Day)
FY2025Q1 (2025-04-23,After Hours):
EPS: 5.63 (Actual) vs.5.55 (Estimate) (1.44%)
Revenue: 646.94M (Actual) vs. 641.78M (Estimate) (0.80%)
Price Reaction: -6.61%(1-Day), -1.79%(5-Day)
FY2024Q4 (2025-02-26,After Hours):
EPS: 6.83 (Actual) vs.6.78 (Estimate) (0.74%)
Revenue: 639.99M (Actual) vs. 636.10M (Estimate) (0.61%)
Price Reaction: 7.39%(1-Day), 9.05%(5-Day)
Earnings Reaction
The chart below shows how CHE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CHE sees a -1.38% change in stock price 10 days leading up to the earnings, and a +0.06% change 10 days following the report. On the earnings day itself, the stock moves by +0.03%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -10.36% on the day following the earnings release and then changed by -7.00% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

Transcript Summary

Chemed Corp (CHE) Q2 2025 Earnings Call Summary
Neutral
2025-07-30
The earnings call presents a mixed picture. Positive elements include VITAS's revenue growth and strategic acquisitions, while negative aspects involve declining Roto-Rooter EBITDA and margin concerns. The Q&A session revealed management's efforts to address issues but also highlighted uncertainties, particularly with Roto-Rooter and VITAS admissions. The lack of detailed guidance and unclear responses create uncertainty, balancing the positive impact of share buybacks and strategic focus. Overall, the sentiment is neutral as the positive and negative factors counterbalance each other, leading to an expected stock price movement within the -2% to 2% range.
Chemed Corp (CHE) Q1 2025 Earnings Call Summary
Positive
2025-04-24
The earnings call reveals strong financial performance for VITAS and Roto-Rooter, with significant revenue and EBITDA growth. Despite challenges like Medicare Cap and competitive pressures, the company has effective strategies to mitigate these risks. The absence of a share buyback program and slightly declining EBITDA margin for Roto-Rooter are minor concerns. The Q&A indicates management's confidence in handling cap issues and cash flow dynamics. Overall, the positive financial metrics and strategic initiatives outweigh the risks, suggesting a positive stock price movement.
Chemed Corp (CHE) Q4 2024 Earnings Call Summary
Neutral
2025-02-27
The earnings call presents mixed signals. Strong financial performance, optimistic guidance, and strategic growth initiatives are positives. However, challenges like margin pressures, competitive pressures on Roto-Rooter, and Medicare Cap limitations pose risks. The Q&A section highlighted management's confidence but also revealed uncertainties, particularly regarding marketing impacts and market entry timelines. The absence of a shareholder return plan further tempers positive sentiment. Overall, the factors balance out, leading to a neutral prediction for stock price movement over the next two weeks.
Chemed Corporation (CHE) Q3 2024 Earnings Call Summary
Neutral
2024-10-30
The earnings call reveals mixed signals. VITAS shows strong financial performance with significant revenue growth and increased EBITDA, but Roto-Rooter faces revenue declines and challenges from marketing transitions and competition. The shareholder return plan lacks buybacks or dividends, and EPS guidance is reduced, but still shows growth from the previous year. The Q&A section highlights cautious optimism for VITAS but ongoing issues for Roto-Rooter. Overall, the positives from VITAS balance the negatives from Roto-Rooter, leading to a neutral prediction for stock movement.
Chemed Corporation (CHE) Q2 2024 Earnings Call Summary
Neutral
2024-07-25
The earnings call reveals mixed signals: strong VITAS growth and optimistic guidance are countered by Roto-Rooter's revenue decline and competitive pressures. The lack of a shareholder return plan and unclear management responses further contribute to uncertainty. The company's expansion efforts and active acquisition pipeline provide potential upside, but risks like regulatory issues and economic factors temper enthusiasm. Overall, the sentiment is balanced, suggesting a neutral stock price reaction.

FAQ

arrow icon

What were the key highlights of CHE’s latest earnings report for FY2025Q2?

CHE reported its FY2025Q2 earnings on 2025-07-29, showcasing a revenue of 618.80M against an estimate of 623.93M, resulting in a -0.82% surprise. The EPS was 4.27, surpassing the expected 4.91 by -13.03% . The stock experienced a -10.36% price change on the earnings day and a -8.9% change over the next five days, reflecting market reactions to the results.
arrow icon

How did CHE’s stock price react after the FY2025Q2 earnings release?

arrow icon

What are the revenue and EPS estimates for CHE for 2025/Q3?

arrow icon

How does CHE’s stock price correlate with earnings forecast revisions?

arrow icon

What should investors expect from CHE’s next earnings report?

arrow icon

What is the sentiment in Chemed Corp (CHE) Q2 2025 Earnings Call Summary?